Terumo Co. (OTCMKTS:TRUMY – Get Free Report) was the target of a large decline in short interest in May. As of May 31st, there was short interest totalling 20,500 shares, a decline of 32.1% from the May 15th total of 30,200 shares. Based on an average daily volume of 210,100 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold.
Terumo Stock Performance
OTCMKTS TRUMY opened at $17.87 on Tuesday. The firm has a market capitalization of $26.46 billion, a P/E ratio of 34.37 and a beta of 0.80. Terumo has a 1-year low of $14.06 and a 1-year high of $21.22. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.94 and a quick ratio of 1.70. The business’s 50-day simple moving average is $18.80 and its 200-day simple moving average is $18.84.
Terumo (OTCMKTS:TRUMY – Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.07). The firm had revenue of $1.79 billion during the quarter, compared to analyst estimates of $1.79 billion.
Terumo Company Profile
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.
Recommended Stories
- Five stocks we like better than Terumo
- How to Evaluate a Stock Before Buying
- New Catalysts to Drive NVIDIA’s Stock Price Even Higher
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
- What Is WallStreetBets and What Stocks Are They Targeting?
- Palantir Defies Bears, Leads S&P 500 in 2025
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.